Summary: Nearly half of cancer patients report disturbances to their circadian rhythms during and after chemotherapy, a problem that can intensify treatment side effects and degrade quality of life. A recent preclinical study using mice finds that paclitaxel, a commonly used breast cancer chemotherapy drug, can alter the brain’s master clock’s molecular and behavioral outputs even without directly penetrating the brain.
In the study, mice treated with paclitaxel showed irregular daily patterns of clock-gene activity and had trouble adjusting their behavior to standard light cues, indicating impaired circadian timing. These results highlight the possibility that maintaining clear day/night cues for patients during chemotherapy could help preserve healthier circadian rhythms and reduce some treatment-related symptoms.
Key Facts:
- Drug Effect: Paclitaxel altered molecular markers and behavioral measures tied to circadian timing in treated mice.
- Clock Disruption: Chemotherapy-treated mice struggled to adapt to light-based circadian cues that normally synchronize daily rhythms.
- Clinical Potential: Providing robust daytime and nighttime cues to patients may help protect circadian organization and lessen side effects, pending further clinical confirmation.
Source: SfN
Background: Circadian rhythms—internal 24-hour cycles that regulate sleep, hormone secretion, metabolism and behavior—are coordinated by a central pacemaker in the brain. Many cancer patients report that these rhythms become disrupted during chemotherapy, and these disturbances often coincide with increased fatigue, sleep problems and other side effects. Because most chemotherapeutic agents do not effectively cross the blood–brain barrier, it has been unclear how systemic chemotherapy might nonetheless perturb the brain’s timing mechanisms.
To investigate this question, researchers led by Leah Pyter at Ohio State University conducted experiments in mice to test whether paclitaxel can interfere with the brain’s clock function and thereby impair circadian rhythms even when drug penetration into the brain is limited.
Study design: The team treated female mice with a paclitaxel regimen chosen to model clinical exposure, focusing on females because breast cancer predominantly affects women. They monitored both molecular markers—specifically, daily expression patterns of genes involved in the circadian system—and behavioral outputs that reflect how well the animals adapt to environmental time cues.
Findings: In untreated animals, genes that govern daily timing typically show robust, predictable fluctuations across the day and night. In contrast, mice receiving paclitaxel displayed irregular expression of these circadian genes within the brain’s master clock region, losing the normal day–night rhythm. Behaviorally, these same mice were slower or less accurate in adjusting their activity patterns in response to changes in light schedules—light being the principal cue that synchronizes the brain’s clock to the external world.
Together, the molecular and behavioral results indicate that paclitaxel disrupts the outputs of the brain’s pacemaker even if the drug itself does not strongly penetrate brain tissue. This pattern suggests indirect pathways—such as systemic inflammation, peripheral signals, or other indirect effects of chemotherapy—might alter central clock function.
Commenting on the results, first author Zoe Tapp said, “The idea that the principal part of the circadian clock in the brain isn’t directly targeted by paclitaxel but is still affected by treatment was new and interesting to see.”
Potential clinical implications: Senior author Leah Pyter emphasized that linking patients’ circadian complaints to underlying changes in brain clock pathways could support practical interventions. “If we can demonstrate that chemotherapy influences the brain circuits that regulate circadian rhythms, then simple, noninvasive strategies—like reinforcing reliable light–dark schedules and strengthening daytime cues—might help reduce fatigue, sleep disruption and other quality-of-life issues during treatment,” Pyter said. She noted that clinical studies will be needed to confirm whether improving daily structure for patients actually diminishes chemotherapy side effects.
About this chemotherapy and circadian rhythm research news
Author: SfN Media
Source: SfN
Contact: SfN Media – SfN
Image: The image is credited to Neuroscience News
Original Research: The findings will appear in eNeuro